Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799711 | 0.89 | CAPN1 (0.47) | CAPN1CTSSCTSKCTSB | |
| SCHEMBL22799717 | 0.89 | CAPN1 (0.47) | CAPN1CTSSCTSKCTSB | |
| SCHEMBL22800999 | 0.81 | CAPN1 (0.47) | CAPN1CTSSMAPTCTSK | |
| SCHEMBL22799838 | 0.78 | ALDH1A1 (0.51) | CAPN1MAPT | |
| SCHEMBL22800194 | 0.77 | CAPN1 (0.47) | CAPN1CTSSCTSKCTSBICMT | |
| SCHEMBL22800133 | 0.74 | LIG1 (0.46) | CAPN1CTSS | |
| SCHEMBL22800223 | 0.71 | ICMT (0.36) | CAPN1MAPTICMT | |
| SCHEMBL22800186 | 0.70 | ICMT (0.37) | CAPN1MAPTGAAATMICMT | |
| SCHEMBL6043415 | 0.70 | TP53 (0.50) | — | |
| SCHEMBL6043222 | 0.68 | ALDH1A1 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | CAPN1 3/4885CTSS 200/4885MAPT 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.